title: Effect of atorvastatin on serum omentin-1 in patients with coronary artery disease.
abstract: OBJECTIVE
  An association between coronary artery disease (CAD) and serum omentin-1 was recently identified. The aim of the present study was to investigate the effect of atorvastatin on serum levels of omentin-1 in patients with CAD.
  
  
  METHODS
  One-hundred and ninety-eight patients with CAD were divided into two groups: those with acute coronary syndrome (ACS) and those with stable angina pectoris (SAP). All patients were randomized to receive atorvastatin therapy at a dose of either 20 or 40 mg/day for 12 weeks. Serum omentin-1 levels and other parameters were determined at baseline and at the end of the study.
  
  
  RESULTS
  Atorvastatin at 20 and 40 mg/day increased serum omentin-1 levels in patients with ACS (20 mg, P=0.007; 40 mg, P<0.001) and in those with SAP (20 mg, P=0.017; 40 mg, P<0.001). Atorvastatin at 40 mg induced greater changes in serum omentin-1 levels compared with 20 mg atorvastatin in both the ACS group (P=0.003) and the SAP group (P=0.012). The increments of serum omentin-1 levels with atorvastatin administration inversely correlated with changes in LDL cholesterol (r=-0.145, P=0.041), interleukin-6 (r=-0.162, P=0.023), and high-sensitivity C-reactive protein (r=-0.185, P=0.009) in patients with CAD. Furthermore, changes in LDL cholesterol (β=-0.158, P=0.027) and interleukin-6 (β=-0.154, P=0.044) remained independent determinants of omentin-1 alterations in standard multiple regression analysis (R=0.122, P=0.006) after adjusting for age, sex, smoking, family history of CAD, and BMI in patients with CAD.
  
  
  CONCLUSIONS
  Atorvastatin increased serum omentin-1 concentrations in patients with CAD in a dose-dependent manner.
authors.affiliation: Departments of aEmergency bBreast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Chen
authors.forename: Xingchen
authors.initials: X
authors.lastname: Shang
authors.forename: Meng
authors.initials: M
authors.lastname: Yuan
authors.forename: Lining
authors.initials: L
authors.lastname: Liang
authors.forename: Xia
authors.initials: X
authors.lastname: Zhong
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D000368:Aged; D060050:Angina, Stable / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D000069059:Atorvastatin / Q000627:therapeutic use*; D002681:China; D003324:Coronary Artery Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016207:Cytokines / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D058851:GPI-Linked Proteins / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D016207:Cytokines; D058851:GPI-Linked Proteins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C432397:ITLN1 protein, human; D037102:Lectins; D000069059:Atorvastatin